This trial is active, not recruiting.

Conditions metabolic syndrome, subclinical organ damage, overweight, obese
Sponsor Goztepe Training and Research Hospital
Start date October 2011
End date April 2012
Trial size 100 participants
Trial identifier NCT01586754, 34


Microalbuminuria and homocysteine levels are shown to be markers for endothelial dysfunction and subclinical organ damage and predictors of cardiovascular risk in several epidemiologic and randomized clinical trials. Carotis intima-media thickness is also found to be elevated in early stages of atherosclerosis. Recent studies have shown correlations between homocysteine, microalbumin levels and carotis intima-media thickness in type 2 diabetics but no data exists for obese or overweight patients who also have metabolic syndrome, in terms of markers of subclinical organ damage. Since obesity is a risk factor for cardiovascular disease and since it is known that patients with metabolic syndrome are at higher risk of cardiovascular events, the investigators wanted to examine whether there is an association between homocysteine, microalbumin levels and carotid intima-media thickness in patients with or without metabolic syndrome, who are either overweight or obese.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective cross-sectional

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: 1. 18-80 years 2. BMI >= 25 3. Ex or non-smokers (must have quit smoking at least 5 years ago) Exclusion Criteria: 1. NIDDM or IDDDM 2. Nephropathy (GFR < 60 ml/min), previous history of coronary artery disease or peripheral arterial disease 3. Current smokers 4. Active infection or other acute illness

Additional Information

Principal investigator ESRA EKIZ, MD
Trial information was received from ClinicalTrials.gov and was last updated in April 2012.
Information provided to ClinicalTrials.gov by Goztepe Training and Research Hospital.